Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2022 · 10-Q
Revenue$13.73M$13.73M+22.3% vs Q1 2021 Net Income-$3.76M-$3.76MN/M vs Q1 2021 EPS Diluted-$0.21-$0.21N/M vs Q1 2021 Gross Profit$8,101,672+32.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow$4,080,244+144.9% Free Cash Flowderived$4,065,764+147.0% Margins · derivedGross margin59.0%+4.5 pt vs Q1 2021
Operating margin-27.4%−21.7 pt vs Q1 2021
Net margin-27.4%−21.7 pt vs Q1 2021
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end